LENZ Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by LENZ Therapeutics, Inc. on June 12, 2026. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Solana Beach, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
As of the record date (April 14, 2026), 31,354,394 shares were outstanding. 24,442,068 shares (approximately 78%) were represented at the meeting.
1. Election of Class II Directors
Three nominees were elected to serve until the 2029 annual meeting. Broker non-votes totaled 3,995,212 for all candidates.
| Nominee | Votes For | Votes Withheld |
|---|---|---|
| Evert Schimmelpennink | 20,216,637 | 230,219 |
| Jeff George | 13,462,359 | 6,984,497 |
| Shelley Thunen | 20,215,686 | 231,170 |
2. Ratification of Independent Auditor
Stockholders ratified the appointment of Ernst & Young LLP for the fiscal year ending December 31, 2026.
| Category | Count |
|---|---|
| Votes For | 24,310,915 |
| Votes Against | 55,181 |
| Abstentions | 75,972 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the significant vote withholding for director nominee Jeff George (approx. 34% of votes cast).
- Confirm the total number of shares outstanding and the record date for future voting calculations.
- Review the full proxy statement for detailed biographies of the newly elected directors.
- Check subsequent filings for the Company's financial performance, as this 8-K contains no financial data.